换一批Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2 weeks in patients with advanced solid tumors.
第一作者：
C S,Higano
第一单位：
Departments of Medicine and Urology, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, USA, thigano@u.washington.edu.
作者：
医学主题词
成年人(Adult);老年人(Aged);抗体, 单克隆(Antibodies, Monoclonal);抗肿瘤药(Antineoplastic Agents);曲线下面积(Area Under Curve);女(雌)性(Female);半衰期(Half-Life);人类(Humans);男(雄)性(Male);最大耐受剂量(Maximum Tolerated Dose);代谢清除率(Metabolic Clearance Rate);中年人(Middle Aged);肿瘤(Neoplasms);受体, IGF1型(Receptor, IGF Type 1)
DOI
10.1007/s10637-015-0217-7
PMID
25749986
发布时间
2025-08-16
- 浏览18
Investigational new drugs
450-62页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
